Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.706 EUR | -0.56% | -1.12% | +64.19% |
08/04 | Sensorion: completion of a private placement | CF |
05/04 | Sensorion SA announced that it expects to receive ?15 million in funding | CI |
Business Summary
Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation.
Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
Number of employees: 57
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 12/17/12 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12 |
Géraldine Honnet
CTO | Chief Tech/Sci/R&D Officer | - | 18/20/18 |
Noémie Djokovic
IRC | Investor Relations Contact | - | - |
Judith Laredo
PRN | Corporate Officer/Principal | - | - |
Valerie Salentey
LAW | General Counsel | - | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cédric Moreau
BRD | Director/Board Member | 37 | - |
Khalil Barrage
CHM | Chairman | 59 | - |
John Furey
BRD | Director/Board Member | 59 | 01/19/01 |
Florian Reinaud
BRD | Director/Board Member | 51 | - |
Director/Board Member | - | 09/15/09 | |
Aniz Girach
BRD | Director/Board Member | 56 | 03/22/03 |
Julien Miara
BRD | Director/Board Member | - | - |
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 12/17/12 |
Director/Board Member | 50 | 24/01 | |
Natalie Berner
BRD | Director/Board Member | 34 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 187,080,794 | 79,138,558 ( 42.30 %) | 0 | 42.30 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SENSORION 0.05% | 144,811 | 0.05% | 120,268 $ |
Company contact information
Sensorion SA
375, rue du Professeur Joseph Blayac
34080, Montpellier
+33 4 67 20 77 30
http://www.sensorion.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.19% | 208M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALSEN Stock
- Company Sensorion